China Oncology ›› 2022, Vol. 32 ›› Issue (8): 698-704.doi: 10.19401/j.cnki.1007-3639.2022.08.004
• Specialists' Commentary • Previous Articles Next Articles
ZHOU Wenbin()(), XIE Hui, DING Qiang, WANG Shui()()
Received:
2022-06-12
Revised:
2022-07-09
Online:
2022-08-30
Published:
2022-09-19
Contact:
WANG Shui
E-mail:zhouwenbin@njmu.edu.cn;shwang@njmu.edu.cn
CLC Number:
ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising[J]. China Oncology, 2022, 32(8): 698-704.
[1] |
YU M X, PAN H, CHE N, et al. Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells[J]. Cell Mol Immunol, 2021, 18(9): 2153-2164.
doi: 10.1038/s41423-020-0449-0 |
[2] |
PHD H S, JACQUES FERLAY MSC M, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660 |
[3] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
doi: 10.3322/caac.21708 |
[4] |
FORNAGE B D, HUNT K K. Image-guided percutaneous ablation of small breast cancer: which technique is leading the pack?[J]. Technol Cancer Res Treat, 2015, 14(2): 209-211.
doi: 10.7785/tcrt.2012.500395 |
[5] |
CHU K F, DUPUY D E. Thermal ablation of tumours: biological mechanisms and advances in therapy[J]. Nat Rev Cancer, 2014, 14(3): 199-208.
doi: 10.1038/nrc3672 |
[6] |
PETROWSKY H, FRITSCH R, GUCKENBERGER M, et al. Modern therapeutic approaches for the treatment of malignant liver tumours[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(12): 755-772.
doi: 10.1038/s41575-020-0314-8 |
[7] |
AHMED M, BRACE C L, LEE F T, et al. Principles of and advances in percutaneous ablation[J]. Radiology, 2011, 258(2): 351-369.
doi: 10.1148/radiol.10081634 |
[8] |
SIMMONS R M, BALLMAN K V, COX C, et al. A phase Ⅱ trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (alliance) Z1072[J]. Ann Surg Oncol, 2016, 23(8): 2438-2445.
doi: 10.1245/s10434-016-5275-3 |
[9] |
CAZZATO R L, DE LARA C T, BUY X, et al. Single-centre experience with percutaneous cryoablation of breast cancer in 23 consecutive non-surgical patients[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1237-1243.
doi: 10.1007/s00270-015-1181-5 |
[10] |
PALUSSIÈRE J, HENRIQUES C, MAURIAC L, et al. Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes[J]. Radiology, 2012, 264(2): 597-605.
doi: 10.1148/radiol.12111303 |
[11] |
FINE R E, GILMORE R C, DIETZ J R, et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial[J]. Ann Surg Oncol, 2021, 28(10): 5525-5534.
doi: 10.1245/s10434-021-10501-4 |
[12] |
SIMON C J, DUPUY D E, MAYO-SMITH W W. Microwave ablation: principles and applications[J]. Radiographics, 2005, 25(Suppl 1): S69-S83.
doi: 10.1148/rg.25si055501 |
[13] |
ZHOU W B, ZHA X M, LIU X A, et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study[J]. Radiology, 2012, 263(2): 364-373.
doi: 10.1148/radiol.12111901 |
[14] |
ZHOU W B, LIANG M D, PAN H, et al. Comparison of ablation zones among different tissues using 2 450 MHz cooled-shaft microwave antenna: results in ex vivo porcine models[J]. PLoS One, 2013, 8(8): e71873.
doi: 10.1371/journal.pone.0071873 |
[15] |
ZHOU W B, JIANG Y N, CHEN L, et al. Image and pathological changes after microwave ablation of breast cancer: a pilot study[J]. Eur J Radiol, 2014, 83(10): 1771-1777.
doi: 10.1016/j.ejrad.2014.06.015 |
[16] |
ZHOU W B, DING Q, LIU X A, et al. Percutaneous microwave coagulation for eradication of VX2 tumors subcutaneously in rabbits[J]. World J Surg Oncol, 2012, 10: 97.
doi: 10.1186/1477-7819-10-97 |
[17] |
KONG P, CHEN L, SHI X, et al. Microwave ablation combined with doxorubicin enhances cell death via promoting reactive oxygen species generation in breast cancer cells[J]. Diagn Interv Imaging, 2018, 99(12): 783-791.
doi: 10.1016/j.diii.2018.06.004 |
[18] |
KONG P, PAN H, YU M, et al. Insufficient microwave ablation-induced promotion of distant metastasis is suppressed by β-catenin pathway inhibition in breast cancer[J]. Oncotarget, 2017, 8(70): 115089-115101.
doi: 10.18632/oncotarget.22859 |
[19] |
SHI X, PAN H, GE H, et al. Subsequent cooling-circulation after radiofrequency and microwave ablation avoids secondary indirect damage induced by residual thermal energy[J]. Diagn Interv Radiol, 2019, 25(4): 291-297.
doi: 10.5152/dir.2019.17455 |
[20] |
ZHOU W B, YU M X, PAN H, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer[J]. J Immunother Cancer, 2021, 9(4): e002343.
doi: 10.1136/jitc-2021-002343 |
[21] |
TOLBA M F, OMAR H A. Immunotherapy, an evolving approach for the management of triple negative breast cancer: converting non-responders to responders[J]. Crit Rev Oncol Hematol, 2018, 122: 202-207.
doi: 10.1016/j.critrevonc.2018.01.005 |
[22] |
EMENS L A. Breast cancer immunotherapy: facts and hopes[J]. Clin Cancer Res, 2018, 24(3): 511-520.
doi: 10.1158/1078-0432.CCR-16-3001 |
[23] |
ROBERT C, RIBAS A, SCHACHTER J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(9): 1239-1251.
doi: 10.1016/S1470-2045(19)30388-2 |
[24] |
ROBERT C, THOMAS L, BONDARENKO I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med, 2011, 364(26): 2517-2526.
doi: 10.1056/NEJMoa1104621 |
[25] |
SCHMID P, RUGO H S, ADAMS S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59.
doi: 10.1016/S1470-2045(19)30689-8 |
[26] |
EMENS L A, CRUZ C, EDER J P, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase Ⅰ study[J]. JAMA Oncol, 2019, 5(1): 74-82.
doi: 10.1001/jamaoncol.2018.4224 |
[27] |
SCHUMACHER T N, SCHREIBER R D. Neoantigens in cancer immunotherapy[J]. Science, 2015, 348(6230): 69-74.
doi: 10.1126/science.aaa4971 |
[28] |
MCARTHUR H L, DIAB A, PAGE D B, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling[J]. Clin Cancer Res, 2016, 22(23): 5729-5737.
doi: 10.1158/1078-0432.CCR-16-0190 |
[29] |
HO A Y, BARKER C A, ARNOLD B B, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer[J]. Cancer, 2020, 126(4): 850-860.
doi: 10.1002/cncr.32599 |
[30] |
VOORWERK L, SLAGTER M, HORLINGS H M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med, 2019, 25(6): 920-928.
doi: 10.1038/s41591-019-0432-4 |
[31] |
DEMARIA S, GOLDEN E B, FORMENTI S C. Role of local radiation therapy in cancer immunotherapy[J]. JAMA Oncol, 2015, 1(9): 1325-1332.
doi: 10.1001/jamaoncol.2015.2756 |
[32] |
BADWE R, HAWALDAR R, NAIR N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial[J]. Lancet Oncol, 2015, 16(13): 1380-1388.
doi: 10.1016/S1470-2045(15)00135-7 |
[33] |
ZHAO J, WEN X F, TIAN L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer[J]. Nat Commun, 2019, 10(1): 899.
doi: 10.1038/s41467-019-08782-1 |
[34] |
DEN BROK M H M G M, SUTMULLER R P M, VAN DER VOORT R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity[J]. Cancer Res, 2004, 64(11): 4024-4029.
doi: 10.1158/0008-5472.CAN-03-3949 |
[35] |
FORMENTI S C, DEMARIA S. Systemic effects of local radiotherapy[J]. Lancet Oncol, 2009, 10(7): 718-726.
doi: 10.1016/S1470-2045(09)70082-8 |
[36] |
SÁNCHEZ-ORTIZ R F, TANNIR N, AHRAR K, et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?[J]. J Urol, 2003, 170(1): 178-179.
doi: 10.1097/01.ju.0000070823.38336.7b |
[37] |
KIM H, PARK B K, KIM C K. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma[J]. Korean J Radiol, 2008, 9(5): 470-472.
doi: 10.3348/kjr.2008.9.5.470 |
[38] |
SOANES W A, ABLIN R J, GONDER M J. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations[J]. J Urol, 1970, 104(1): 154-159.
doi: 10.1016/S0022-5347(17)61690-2 |
[39] |
MCGAHAN J P, BROCK J M, TESLUK H, et al. Hepatic ablation with use of radio-frequency electrocautery in the animal model[J]. J Vasc Interv Radiol, 1992, 3(2): 291-297.
doi: 10.1016/S1051-0443(92)72028-4 |
[40] |
LI L, WANG W, PAN H, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer[J]. J Transl Med, 2017, 15(1): 23.
doi: 10.1186/s12967-017-1124-9 |
[41] |
ZHU J, YU M, CHEN L, et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: a pre-clinical study in a murine model[J]. Diagn Interv Imaging, 2018, 99(3): 135-142.
doi: 10.1016/j.diii.2017.12.011 |
[42] | ZHOU W B, YU M X, MAO X R, et al. Landscape of the peripheral immune response induced by local microwave ablation in patients with breast cancer[J]. Adv Sci (Weinh), 2022, 9(17): e2200033. |
[43] |
HAEN S P, GOUTTEFANGEAS C, SCHMIDT D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation[J]. Cell Stress Chaperones, 2011, 16(5): 495-504.
doi: 10.1007/s12192-011-0261-y |
[44] |
GU T, GE Y, SONG Y Z, et al. Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma[J]. Scand J Clin Lab Invest, 2015, 75(7): 621-627.
doi: 10.3109/00365513.2015.1050689 |
[45] | LI G F, STAVELEY-O’CARROLL K F, KIMCHI E T. Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma[J]. J Clin Trials, 2016, 6(2): 257. |
[1] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[2] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[3] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[4] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
[5] | ZHANG Yu, LIU Qiang. Advances of liquid biopsy in precision treatment of breast cancer [J]. China Oncology, 2022, 32(8): 688-697. |
[6] | LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda. Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis [J]. China Oncology, 2022, 32(8): 705-711. |
[7] | XIAO Jialong, MO Miao, ZHOU Changming, WANG Zezhou, SHEN Jie, YUAN Jing, YU Keda, LIU Guangyu, WU Jiong, SHEN Zhenzhou, SHAO Zhimin, ZHENG Ying. The effect of the interaction between body mass index and age on the prognosis of breast cancer [J]. China Oncology, 2022, 32(8): 719-726. |
[8] | CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang. Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer [J]. China Oncology, 2022, 32(8): 727-735. |
[9] | LIU Qiang, FANG Yi, WANG Jing. Application progress of single-cell sequencing technology in breast cancer research [J]. China Oncology, 2022, 32(7): 635-642. |
[10] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[11] | SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486. |
[12] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[13] | JIA Xiaoqing, SUN Xiaoyin, JIANG Beiqi, MEI Zhangyi, FU Yun, ZHUANG Zhigang. Neddylation modification regulates lamin B1 expression in breast cancer [J]. China Oncology, 2022, 32(6): 535-541. |
[14] | LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer [J]. China Oncology, 2022, 32(5): 417-426. |
[15] | ZHANG Qian, FANG Xiaoyan, LIU Juan, LIU Jin, CHENG Leilei, SUN Jing. Study on the safety of simultaneous integrated boost and the importance of cardiac substructural dose assessment of hypofractionated radiotherapy after early left breast cancer breast-conserving surgery [J]. China Oncology, 2022, 32(5): 427-435. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd